Immunotherapy is an important breakthrough in malignancy. not result in short-term changes in standard disease progression end points (eg, progression-free survival, tumor size), which may be explained, in part, by the time taken for antigen spread to occur. Thus, immune-related response criteria need SB 203580 distributor to be recognized to better monitor the effectiveness of… Continue reading Immunotherapy is an important breakthrough in malignancy. not result in short-term